



Dear Sir/Madam,

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Subject : Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026

Stock Code : BSE – 539787, NSE – HCG

Reference : Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that the Board of Directors of the Company, at their meeting held today i.e. August 06, 2026, inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 (“Financial Results”).

We enclose herewith the Investor Presentation on the Financial Results of the Company.

The above information is also available on the website of the Company and can be accessed at:
<https://www.hcgoncology.com/investor-relations/>

You are requested to take the information on record.

Thanking you,

For **HealthCare Global Enterprises Limited**

SUNU

MANUEL ABEY

Digitally signed by SUNU
MANUEL ABEY
Date: 2026.08.06 20:36:11
+05'30'

Sunu Manuel

Company Secretary & Compliance Officer

Encl:a/a



HEALTHCARE GLOBAL ENTERPRISES LIMITED

Q1 FY2027 Results Presentation

August 6, 2026





This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.





Strategic Progress Over the Past Year

Executing Our Strategy | Building the Foundation for Sustainable Long-Term Value Creation



Focus on core oncology

Completed Strategic Exit from Milann

- ✓ Sharpened focus on core-oncology
- ✓ Enhanced management focus and execution
- ✓ Strengthening clinical differentiation



Capacity expansion

North Bengaluru Hospital Operational

- ✓ 120+ beds capacity added in May 26
- ✓ State-of-the-art MR-LINAC commissioned
- ✓ Strengthens leadership in Bengaluru market



Capital strength

Successfully Completed Rights Issue

- ✓ Strengthened Balance sheet
- ✓ Enhanced financial flexibility
- ✓ Well positioned to fund future growth



Leadership

Management Team Strengthened

- ✓ Leadership team fully on-boarded
- ✓ Execution capability strengthened
- ✓ Enhanced institutional governance



Growth pipeline visibility

Bed Expansion Progressing

- ✓ Brownfield expansion in high potential centers
- ✓ Unlocking embedded capacity across network
- ✓ Return focused capital investment



Operational excellence

Key Initiatives Underway


- ✓ Cost optimization
- ✓ Driving productivity improvements
- ✓ Enhancing patient experience




Q1 FY27: Performance Update

Revenue grew 13% y-o-y, while Adjusted EBITDA grew 20% y-o-y, with margins improving to 19.4% compared to 18.2% in Q1 FY26

Financial Highlights



Operational Highlights



Notes:

- Adjusted EBITDA excludes North Bangalore Loss of INR 70 Mn and EPCG-related provision of INR 45.9 Mn in Q1 FY27 and ESOP of INR 14.5 Mn and M&A-related costs of INR 25.6 Mn in Q1 FY26
- Profit after Tax is profit attributable to the owners of the company



HCG Key Highlights: Q1 FY27

HCG delivered revenue of INR 6,951 Mn in Q1FY27, reflecting ~13% YoY growth

- Broad-based growth continued across clusters in Q1FY27. Revenue growth was led by volume growth of 11% y-o-y. ARPP grew by 2%, improvement driven by a favourable payor mix was partly offset by changes in case mix, including a lower contribution from high-value, low-margin therapies
 - **South** Revenue of INR 2,765 Mn (contributing 40% of revenue) delivered ~16% YoY growth
 - Balanced growth from volume and realization. Bangalore CoE and MGCH in AP region witnessed improvement in Cash + TPA mix
 - **West** Revenue of INR 3,010 Mn (contributing 43% of revenue) delivered ~9% YoY growth.
 - Strong revenue growth in Maharashtra region was offset by moderated growth in Gujarat region
 - Led by increase in patient volumes (10% YoY growth). ARPP was impacted due to higher share of medical oncology and rationalization of high-value, low-margin therapies
 - **East** Revenue of INR 799 Mn (contributing 11% of revenue) grew ~22% YoY
 - Higher patient volumes (25% YoY growth). ARPP declined 3% YoY due to case-mix changes and a higher contribution from state-government schemes
- International business revenue was INR 208 Mn, grew ~9% YoY in Q1FY27, driven by stronger patient inflows for radiation oncology and PET cases
- Fertility Business divested in June 26; delivered revenue of INR 169 Mn and EBITDA of INR 23 Mn in Q1 FY27

HCG delivered Adjusted EBITDA¹ of INR 1,339 Mn in Q1FY27, up ~20% YoY

- Adjusted EBITDA¹ margin **improved to 19.4% in Q1 FY27 from 18.2% in Q1 FY26**, driven by continued improvement in quality of revenue
- Reported EBITDA was INR 1,223 Mn impacted due to start up losses of North Bangalore facility amounting to INR 70 Mn and EPCG related provision of INR 46 Mn

Key Business Developments:

1. North Bangalore Launched

- **Successfully commenced operations** in May 2026 with 56 operational beds, potential to expand bed capacity to 120+ beds
- **Strong traction** post launch with 550+ New Patient registrations, 300+ admission and **Revenue of INR 67 million in the first quarter**
- **MR Linac commissioned in July 2026**, making the centre home to one of India's most advanced adaptive radiation therapy platforms and expected to further enhance clinical capabilities and drive patient volume

2. Total 121 operational beds added, comprising of 56 beds at North Bangalore, 26 beds at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya


3. Rajkot Upgrade: Enhanced clinical capabilities with the operationalization of a new LINAC, transforming Rajkot into a Comprehensive Cancer Care (CCC) Centre

4. Robotics Expansion: Strengthened robotic surgery capabilities with the addition of new surgical robotic systems at Nashik and replacement at Bangalore CoE



Financial Highlights: Q1 FY27

Overall Revenue




Adjusted EBITDA¹


Margin (%)

18.2%


19.4%



Volumes (excl. Fertility)²



Revenue (excl. Fertility)²




Adjusted EBITDA¹ (excl. Fertility)²


Margin (%)

18.4%

19.6%




ARPP (excl. Fertility)²






Revenue Mix By Specialty and Payor: Q1 FY27

Specialty Mix Trend




Payor Mix : Increasing Share of Cash & TPA Business in Line with Stated Strategy




Notes:
(1) Modality mix: Excludes fertility business (2) OP + Other services : Includes OPD consultation, diagnostics, pharmacy and IPD related supportive care treatment (3) Payor mix excludes Fertility & International Business



Region-wise Performance Update: South





Q1 FY27





Q1FY27 Highlights:

- Revenue increased 16% YoY to INR 2,765 million, led by Bangalore CoE and MGCH Vizag and supported by the North Bangalore facility, which commenced operations in May 2026 and contributed INR 67 million in Q1 FY27
- Volume grew 7% YoY. The Bengaluru CoE grew 14%, with growth across modalities







Region-wise Performance Update: West




- Q1FY27 Highlights:**
- Revenue increased 9% YoY to INR 3,010 million. Strong performance in Maharashtra was partly offset by slower growth in Gujarat
 - Volume grew 10% YoY, supported by an improved payor mix
 - Payor-mix benefits were offset by higher share of medical oncology volumes and focus away from high value, lower margin therapies, leaving ARPP broadly stable




(1) Bed share represents Operating beds (Census + Non-Census)





Region-wise Performance Update: East



Q1 FY27



- Q1FY27 Highlights:**
- Strong revenue growth of 22% YoY, supported by healthy patient volume growth and continued market penetration
 - ARPP declined 3% YoY due to case-mix changes and a higher contribution from state-government schemes



(1) Bed share represents Operating beds (Census + Non-Census)

HCG: Growth Plans and Strategic Priorities



Bed Addition: 1,000 beds by FY30, led by 60% brownfield expansion



31 st Mar'26		FY27	FY28 & FY29		FY30	FY30 P	
No. of Operational Beds¹	2,734	188 Bed addition	~520 Bed addition		~230 Bed addition	~3,670	
		Capex ~INR 1,500 Mn	Capex ~INR 3,000 Mn		Capex ~INR 1,000 Mn		
		92 Greenfield: North Bangalore	96 Brownfield beds	~180 Upcoming Greenfield projects	~340 Brownfield beds	~100 Upcoming Greenfield project	~130 Brownfield beds
		- North Bangalore operationalized in Q1'27 26 beds added at Ranchi, 19 at Borivali, 8 at Nashik, 5 at Hubli, 7 at Kenya 18 beds to be operationalized at Bangalore CoE and 13 at Kenya	- Two greenfield projects in pipeline - Additional beds to be added at Suchirayu (50), Jaipur (30), Nagpur (27), HCC Ahmedabad (23) - Brownfield capacity addition at Cuttack (75), Vizag (50)		- One Greenfield project ~130 brownfield beds across ~7 existing facilities to be ramped in a phased manner		
		Greenfield Brownfield					
No. of LINACs	38	2 Linac North Bangalore, Kenya		2 Linac 2 Greenfield projects		1 Linac Greenfield project	~43


Note:

1. Operational beds are Revenue generating beds and non-census

2. Bed Capex excludes maintenance capex



Strategic Priorities To Accelerate Long-Term Value Creation





Q1FY27 Consolidated Profit & Loss

Profit and Loss (INR in Mn.)	Q1FY27	Q1FY26	Y-o-Y	Q4FY26
Revenues from Operations	6,933.9	6,118.0		6,502.9
Income from Govt. Grant	17.1	13.6		20.4
Total Revenue from Operations	6,951.0	6,131.6	13.4%	6,523.3
Cost of Goods Sold	1,788.0	1,618.7		1,767.1
Employee Cost	1,045.2	977.7		924.7
Medical Consultancy Charges	1,574.7	1,330.2		1,403.3
Other Expenses	1,320.5	1,127.1		1,177.4
Reported EBITDA	1,222.6	1,077.9	13.4%	1,250.8
Reported EBITDA Margin (%)	17.6%	17.6%	-	19.2%
North Bangalore losses	70.2	Na	Na	Na
One time cost	45.9	25.6		1.5
ESOP's	-	14.5		-
Adjusted EBITDA	1,338.7	1,118.0	19.7%	1,252.3
Adjusted EBITDA Margin (%)	19.4%	18.2%	+121 bps	19.2%
Depreciation	704.2	579.1		628.1
Other Income	121.3	68.3		130.7
EBIT	639.7	567.1	12.8%	753.4
Finance Cost	398.7	454.7		427.0
Extraordinary Items	-	-		319.1
Share in Profit/(loss) in JV and Associates	9.3	6.8		5.2
Profit before Tax	250.3	119.2	110%	12.5
Taxes & Non controlling interest	112.6	71.7		9.2
Profit After Tax	137.7	47.5	190%	21.7
PAT Margin (%)	2.0%	0.8%	+121 bps	0.3%
Adj. Profit After Tax⁽¹⁾	137.7	47.3	190%	340.8
Adj. PAT Margin (%)	2.0%	0.8%	+121 bps	5.2%
EPS (On reported PAT)	0.92	0.34		0.15

Note: (1) Q4FY26 Adjusted PAT (post Non controlling interest) is normalized for goodwill impairment of fertility business (INR 319mn)



Q1FY27 Operational Metrics



Key Metrics	South		West		East		Consolidated ¹	
	Q4FY26	Q1FY27	Q4FY26	Q1FY27	Q4FY26	Q1FY27	Q4FY26	Q1FY27
Bed Capacity	1,343	1,483	1,440	1,440	333	359	3,131	3,304
Operational Beds	1,238	1,299	1,163	1,190	318	344	2,734	2,855
Census Beds ²	942	991	1,066	1,093	310	334	2,333	2,440
In-Patient Volume	31,723	32,915	30,249	31,789	11,095	12,296	74,748	78,914
ARPP (INR)	82,169	84,001	94,710	94,702	63,018	64,983	85,176	85,943

Note:


1.Consolidated is including the International business (Kenya operations) and excluding fertility business

2.Census beds comprises of Revenue generating beds including IPD/Ward beds and Chemo beds

HCG: India's Leading Oncology Platform




A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment



Underpinned by a personalized patient-centric approach, superior technology, and industry leading medical excellency



1. Largest Pan-India Oncology Focused Hospital Chain



Largest Geographical Reach...

• 19 /10 •

Number of Cities and
states covered¹

• 26 •

No. of
hospitals³

• 3k+ •

Capacity
beds³

• 16/19 •

Leading
positions²

...With Leading Treatment Infrastructure

• 38 •

Number
of LINACs⁴

• 20 •

Number
of PET CTs

• 105 •

Operation
theatres³

• 11 •

Number of Robotic
machine⁵



2. Preferred Platform for Leading Oncology Specialists



Integrated Oncology Ecosystem

Full time and exclusive
Oncologist

Integrated Medical,
Surgical & Radiation
Oncology teams

Organ specific Oncology
teams

Precision Medicine with
clinical protocols

**Preferred destination for leading oncologists
to deliver advanced cancer care**

Focused Specialty with Scale

Oncology-specific
clinical pathways

Strong referral network

Higher case complexity
and treatment volumes

Superior clinical
outcomes

**Specialized network impact > better
outcome> more referrals > higher doctor
satisfaction**

Clinical Excellence and Academics

Access to cutting-edge
technologies

High degree of clinical
autonomy

Strong research and
academics ecosystem

Experienced peer group

**Research and collaboration reinforce
superior clinical outcomes**



450+

Revenue generating Oncologists



350+ robotic surgeries

Total of ~12k Surgeries as of Q1'27



1000+

Paper Published till date



38

LINAC's



88%

Doctor Retention Rate in FY26




30+

New Clinical Trials in FY2026



3. Introducing Latest Medical Technology in Cancer Care

TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED TECHNOLOGY IN INDIA



Introducing organ-specific working committees – gastrointestinal, head & neck, breast, etc. for better data collection & analysis to improve patient outcome

State-of-the-art Equipment in each modality

DIAGNOSTICS

Total PET CTs : 20



Digital PET



Digital CT Pathology



Automated Breast Volume Scanner



Digital Mammography



Skyra Tesla 3T for MRI



Molecular / Genomics Lab

RADIOTHERAPY

Total LINACs : 38



Cyber Knife



MR-LINAC



True Beam



Versa HD



Radixact



Tomotherapy

MEDICAL/SURGICAL ONCOLOGY

Total Robots: 11



Da Vinci Robot



Versius Robot



Holo Lens



Bone Marrow Transplant Units



4. Tumor Board Approach to Deliver Customized Treatment

Spearheaded by Dr. Ajai, who also heads IRC¹ of 30+ oncologists for Investigator Initiated Research Studies

17+ years of nation-wide **Tumor Boards** held weekly

Supplemented by multiple **local tumor boards**

Multi-disciplinary Tumor Board ...

... Takes Inputs From Large Network ...

... Is Patient Focused



250+

Oncologists participated



36K+

Cases discussed till date

Decision Making Body

Tumor board
Convenor

Chairman

Special committee

Panelists

Leading Oncologists

Radiologists/
Pathologists

Clinical Experts and
academicians

Participants

Treating clinicians

Support Specialities²

All other clinicians



Highly
specialized
team



Patient
centric



End-to-
end
services



Accuracy
and
reliability

Case Selection

Preparation

Deliberation

Execution



5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship

Diagnostics

Treatment

Post Care



**Genomics and
Molecular
diagnostics**



Digital PET




**Preventive
Oncology**




**Medical Oncology
and Haemato-
Oncology**



Radiation Oncology



**Surgical
Oncology**




**Molecular Imaging
and Theranostics**



**Psychological
support**



**Preventive
Oncology**



Physical
Examination



Laboratory
Tests



Home Health
Services




Digital
Pathology



Digital
PET




Preventive
Oncology



Genomics




CTC¹ detection




Chemotherapy




Radiation



Robotic Surgery



Actinium and
Lutetium therapy




Immunotherapy




Psycho-
oncology




Liver
Transplant




Iodine
Therapy




Targeted Drug
Therapy




Pediatric
Oncology




Organ preservation
& Reconstructive
surgery




Endocrine
Therapy




Patient
Care



Home Health
Services



Psychological
Support




Preventive
Oncology



Nutrition



Rehab



Genetic
Counselling



6. Experienced Board of Directors



Dr. BS Ajai Kumar

Founder and Non-Executive Chairman

Visionary and key driving force of HCG, with an aim to make advanced cancer care accessible



Dr Manish Mattoo

Executive Director and CEO

Seasoned healthcare leader with 20+ years of clinical & business expertise driving healthcare management



Akshay Tanna

Non-Executive Director

Partner at KKR with 20+ years of investing and finance experience. Board member at JB Pharma, BMH, Healthium, Avendus, etc.



Simrun Mehta

Non-Executive Director

Managing Director at KKR, serving on Boards of Vini Cosmetics, Lighthouse Learning, Avendus, BMH etc.



Anjali Ajaikumar Rossi

Non-Executive Director

Social entrepreneur with over 15 years in healthcare; focused on quality and strategy



Geeta Mathur

Non-Executive Independent Director

Experienced finance professional, serving on Boards of Ashok Leyland, Info Edge, JSW One, IIFL group etc.



Rajagopalan Raghavan

Non-Executive Independent Director

30+ years of leadership experience. Currently serving as Chief Human Resource Officer at CoreStack



Pradip Kanakia

Non-Executive Independent Director

36+ years in audit and governance and have held leadership positions in Price Waterhouse, KPMG. On the Board of JM Financial, Britannia Industries, ICRA Limited etc.



Rajiv Maliwal

Non-Executive Independent Director

Founder of Sabre Partners with 30+ years of investment experience. Board member at Wellspring Healthcare, Monepeak Fintech etc.




Bijou Kurien

Non-Executive Independent Director

Consumer industry leader with 40+ years experience across Titan & Reliance Retail. Board member & advisor to multiple companies



HCG Shareholding Pattern and Key Shareholders



Top Institutional Investors as on 30th June 2026



* All logos are for representation purpose only and copyright belong to the respective owners



Key Metrics	Definitions
Bed Capacity	Bed Capacity reflects total beds that can be accommodated in the hospitals
Operational / Census Beds	Operational beds comprises of Census and non-census beds
Census Beds	Revenue generating beds including IPD/Ward beds and Chemo beds
Non-Census Beds	Transient Beds including Emergency, triage, pre-op/post op etc
Volume	In-patient volume includes IPD volumes, Chemo cycle and Radiation volume
ARPP (In INR)	Revenue from Operations / In-patient Volume



CIN: L15200KA1998PLC023489

About Us: HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Kenya, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof.

For updates and specific queries, please visit www.hcgoncology.com or contact:

HealthCare Global Enterprises Limited
investors@hcgoncology.com

Ravi Gothwal
Head Investor Relations
Ravi.gothwal@hcgel.com
Tel: +91 95996 55711

Anoop Poojari / Suraj Digawalekar
CDR India
anoop@cdr-india.com / suraj@cdr-india.com
Tel: +91 98330 90434 / +91 98211 94418



THANK YOU
